Ash set to launch Cordis treatment for heart disease

Healthcare giant Johnson & Johnson's Cordis arm has appointed Ash Communications to launch its latest treatment for heart-disease patients.

The agency has been asked to support the UK launch of the firm's latest stent, Cypher - a device inserted into the body to widen the coronary artery and improve bloodflow to the heart.

The treatment assists those suffering from coronary artery disease, predominantly caused by fatty materials clogging the arteries.

The disease is the major cause of death in the UK, accounting for 22 per cent of all deaths. The use of stents is often preferred to more invasive treatments such as open-heart surgery.

The new product, which will launch later this year, aims to reduce complications during the procedure, including restenosis - when the artery rejects the insertion of the stent and narrows further.

As part of the promotional work for its launch, Ash will target healthcare professionals and councils, and attempt to educate patients on the nature of the product. The agency will also work alongside PA shop Portcullis Research to boost awareness of the product within government.

The agency will earn fees of £100,000 for the nine-month brief, reporting to Moira Randles, business director for the firm's cardiology unit.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in